Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

Keros Therapeutics, Inc. (NASDAQ:KROS) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 4,260,000 shares, a growth of 6.0% from the January 15th total of 4,020,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is presently 2.8 days.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Braidwell LP boosted its holdings in shares of Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after buying an additional 1,187,199 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares during the period. Lynx1 Capital Management LP acquired a new position in shares of Keros Therapeutics in the fourth quarter valued at approximately $8,612,000. Millennium Management LLC boosted its holdings in shares of Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock valued at $13,901,000 after buying an additional 305,169 shares during the period. Finally, Alkeon Capital Management LLC boosted its holdings in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares during the period. 71.56% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KROS has been the subject of several recent analyst reports. Truist Financial decreased their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Scotiabank decreased their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Jefferies Financial Group started coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating for the company. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Trading Up 1.7 %

Shares of NASDAQ KROS opened at $10.32 on Tuesday. Keros Therapeutics has a 1-year low of $9.77 and a 1-year high of $73.00. The company has a market cap of $418.06 million, a PE ratio of -1.98 and a beta of 1.39. The company has a 50-day moving average of $15.78 and a two-hundred day moving average of $41.71.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.